TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Lexaria Bioscience ( (LEXX) ).
Lexaria Bioscience Corp. has extended its Material Transfer Agreement with a pharmaceutical company to further evaluate its DehydraTECH technology in a pre-clinical setting. This extension allows for continued collaboration and strategic planning as the pharmaceutical company reviews data from Lexaria’s Australian study, with final results expected by the end of 2025. This development could enhance Lexaria’s industry positioning by demonstrating the efficacy and safety of its technology, potentially impacting stakeholders by solidifying partnerships and advancing clinical applications.
The most recent analyst rating on (LEXX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, known for its patented DehydraTECH technology, which enhances the oral delivery of drugs by improving bio-absorption, reducing side effects, and facilitating drug delivery across the blood-brain barrier. The company operates a licensed research laboratory and holds a substantial intellectual property portfolio with 54 patents granted worldwide.
Average Trading Volume: 578,547
Technical Sentiment Signal: Strong Sell
Current Market Cap: $24.67M
For a thorough assessment of LEXX stock, go to TipRanks’ Stock Analysis page.